论文部分内容阅读
目的通过对甲亢患者服用碳酸锂后甲状腺摄131I率变化的观察,探讨碳酸锂对低摄131I率或快转换率甲亢患者的应用价值。方法选取32例低摄131I率甲亢患者口服碳酸锂250 mg,3次/d,餐后服用,连服7 d,分别在服用前、后进行甲状腺摄131I率测定,计算计划给131I量,并比较两次差别。结果 32例患者在服用碳酸锂后甲状腺的摄131I率比服用前明显升高,用131I剂量减少,差异具有统计学意义(P<0.01)。结论碳酸锂能够提高低摄131I率甲亢患者的甲状腺摄131I率,延长131I在甲状腺内的滞留时间,满足了患者服131I治疗的要求并减少了同位素131I的治疗用量,具有实用推广价值。
Objective To investigate the value of 131I change of 131I in thyroid after taking lithium carbonate in patients with hyperthyroidism and to explore the value of lithium carbonate in patients with hyperthyroidism with low 131I or fast conversion rate. Methods Thirty-two patients with hypothyroidism and 131I hyperthyroidism were enrolled in this study. Oral lithium carbonate 250 mg orally for 3 times per day was given after meal for 7 days. The 131I dose of thyroid was measured before and after taking 131I dose. Compare two differences. Results Thirty-two patients had significantly higher 131 I-uptake of thyroid after taking lithium carbonate than those before taking 131 I, and the difference was statistically significant (P <0.01). Conclusion Lithium carbonate can improve the 131I rate of thyroid in patients with hyperthyroidism at low 131I and prolong the residence time of 131I in the thyroid. It can meet the requirement of 131I treatment and reduce the dosage of isotope 131I, which is of practical value in popularization.